When it comes to fertility, knowledge and access to the right care can make all the difference. That’s why we’re thrilled to announce that Fertilysis will be part of the Canadian Fertility Show on October 18th, 2025, in Toronto.

We’ve expanded our KIR–HLA compatibility testing to include maternal HLA-C typing alongside paternal HLA-C. This update provides a more complete immune compatibility evaluation and reflects our commitment to moving beyond standard. New evidence shows that maternal HLA-C matters too. That’s why we’ve added it to our KIR–HLA testing — delivering a more comprehensive and clinically meaningful assessment for immune-related fertility risks.

For years, women have been told to wait until they’ve had three consecutive miscarriages before any proper investigation begins. This “rule of three” is something we see all too often—and it frustrates us deeply. Because this isn’t just a number. It’s three devastating losses, three emotional rollercoasters, and three missed chances to identify and resolve the issue earlier.

Let us be clear: There is no scientific or ethical justification for waiting until three miscarriages to start testing. This policy isn’t medically sound—it’s economically motivated. It was created within national healthcare systems to manage budgets, not to protect your future family. It’s a cost-control method disguised as a care standard. Especially when private, self-funded testing options are available.